Company news
Clinuvel Pharmaceuticals Limited news in 2016
Clinuvel Pharmaceuticals Limited's news releases, calls and decks from 2016, newest first.
CLINUVEL agrees with FDA on New Drug Application timelines
November 8, 2016
SCENESSE - NICE England Update
October 17, 2016
FDA Schedules Pre-NDA Meeting for SCENESSE
October 12, 2016
Clinuvel completes combination therapy pre-clinical study
August 3, 2016
FDA accept SCENESSE clinical data package for NDA submission
July 18, 2016
FDA awards SCENESSE Fast Track designation for EPP treatment
July 5, 2016
SCENESSE launched in Europe
June 22, 2016
SCENESSE Treatment in Europe
May 18, 2016
SCENESSE attains breakthrough European Market Authorisation
March 30, 2016
US patent for alpha-MSH and analogues
March 30, 2016
Patent to assist drug as potential skin cancer preventative
March 30, 2016
Clinuvel to evaluate SCENESSE as therapy in vitiligo
March 30, 2016
Clinuvel - strategic focus of final regulatory program
March 30, 2016
Clinuvel selects leading US manufacturing partner
March 30, 2016
Clinuvel reports positive results in Phase III EPP trial
March 30, 2016
FDA provides positive guidance on Clinuvel`s EPP program
March 30, 2016
EMA acknowledges Clinuvel filing afamelanotide in Europe `11
March 30, 2016
Clinuvel records first A$1 million in sales
March 30, 2016
Clinuvel presents SCENESSE to global porphyria conference
March 30, 2016
Clinuvel granted Australian formulation patent
March 30, 2016
Clinuvel completes first Phase II US study
March 30, 2016
Clinuvel books European Pre-Submission Meeting for SCENESSE
March 30, 2016
Response to ASX price query
March 30, 2016
Observations from Clinuvel`s programs being presented at AAD
March 30, 2016
Clinuvel - positive results from pivotal Phase III EPP study
March 30, 2016
Clinuvel granted US topical formulation patent
March 30, 2016
Clinuvel files European MAA for SCENESSE (afamelanotide)
March 30, 2016
Clinuvel completes pre-clinical program for SCENESSE
March 30, 2016
Clinuvel commences US Phase III trial of SCENESSE
March 30, 2016
Clinuvel announces positive results of Phase II US study
March 30, 2016
Appendix 4E - Preliminary Final Report
March 30, 2016
Appendix 4D - Half Yearly Report
March 30, 2016
SCENESSE successful in Phase IIa vitiligo study
March 30, 2016
Placement
March 30, 2016
Observations from Clinuvels US vitiligo study published
March 30, 2016
Five month study follow up - SCENESSE in vitiligo (CUV102)
March 30, 2016
Clinuvel clears EMA manufacturing audit
March 30, 2016
US orphan-drug designation in Hailey-Hailey Disease
March 30, 2016
Phase II vitiligo study commences in Singapore
March 30, 2016
Media Release- Clinuvel successful in US Phase III trial
March 30, 2016
EMA review of SCENESSE extended to mid-2014
March 30, 2016
Clinuvel placement
March 30, 2016
Clinuvel declines unsolicited proposal from Retrophin
March 30, 2016
JAMA Dermatology publishes SCENESSE vitiligo study results
March 30, 2016
EMA Oral Explanation Update
March 30, 2016
Clinuvel enters a joint venture with Biotech Lab Singapore
March 30, 2016
Clinuvel accredits first European EPP expert centres
March 14, 2016
Clinuvel Placement
March 14, 2016
Clinuvel brief on European commercialisation
February 15, 2016
US FDA orphan designation received for cutaneous porphyrias
February 11, 2016
Decks in 2016
- Shareholder Meeting (November 2016)
Shareholder meeting · 28 slides · Nov 28, 2016
- Investor Presentation (February 2016)
Investor deck · 25 slides · Feb 8, 2016